GLP1R and diabetes mellitus: Safety signals for GLP-1 receptor agonists are generally favorable, with established results in diabetes care, but their translation into neurodegeneration requires careful monitoring for gastrointestinal side effects, weight loss, and cardiovascular effects that may confound neurological outcomes [113,114].